

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 July 2005 (21.07.2005)

PCT

(10) International Publication Number
WO 2005/065685 A1

(51) International Patent Classification⁷: A61K 31/43, 9/26

MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:
PCT/IN2005/000005

(22) International Filing Date: 5 January 2005 (05.01.2005)

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
22/DEL/2004 6 January 2004 (06.01.2004) IN
27/DEL/2004 6 January 2004 (06.01.2004) IN

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (for all designated States except US): PANACEA BIOTEC LTD. [IN/IN]; B-1 Extn./A-27, Mohan Co-operative Industrial Estate, Mathura Road, New Delhi 110 044 (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): JAIN, Rajesh [IN/IN]; Panacea Biotec Ltd., B-1 Extn./A-27, Mohan Co-operative Industrial Estate, Mathura Road, New Delhi 110 044 (IN). JINDAL, Kour, Chand [IN/IN]; Panacea Biotec Ltd., B-1 Extn./A-27, Mohan Co-operative Industrial Estate, Mathura Road, New Delhi 110 044 (IN). SINGH, Sukhjeet [IN/IN]; Panacea Biotec Ltd., B-1 Extn./A-27, Mohan Co-operative Industrial Estate, Mathura Road, New Delhi 110 044 (IN).

(74) Agent: GUPTHA, Bhartee; Panacea Biotec Limited, B-1 Extn., A-27, Mohan Co-operative Industrial Estate, Mathura Road, New Delhi 110 044 (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,

(54) Title: CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION COMPRISING AN ACID-INSOLUBLE AND A BIOADHESIVE POLYMER

(57) Abstract: Rapidly disintegrating oral controlled release pharmaceutical compositions and process for preparation of such compositions are provided. The compositions preferably comprise antibiotic(s) as active ingredient, more preferably amoxicillin either alone or in combination with other antibiotic(s). The controlled release compositions comprise at least one active ingredient, and a polymer system comprising of at least two polymers which retard the release of the active ingredient in the stomach while providing rapid release of the said active ingredient in the alkaline contents of small intestine, optionally with other pharmaceutically acceptable excipients. The compositions provide therapeutically effective levels of the active ingredient for extended periods of time, and possess bioadhesive properties.

WO 2005/065685 A1

CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION COMPRISING AN ACID-INSOLUBLE AND
A BIOADHESIVE POLYMER

Field of the invention

The present invention relates to controlled release pharmaceutical compositions and process for preparation of such compositions, preferably comprising antibiotic(s) as
5 active ingredient, more preferably Amoxicillin either alone or in combination with other antibiotic(s). The controlled release compositions are of disintegrating type, and additionally possess mucoadhesive properties.

The controlled release composition is useful in providing therapeutically effective levels of the said active ingredient for extended periods of time. Moreover the said composition
10 is expected not to compromise the bioavailability of the active ingredient under fed or fasted conditions.

Background of the invention

Amoxicillin is a beta-lactam widely used as a broad-spectrum antibiotic for treatment of a variety of common bacterial infections. Amoxicillin has known susceptibility to
15 inhibition by beta-lactamases produced by resistant organisms. Amoxicillin is available in a variety of formulations, for instance as capsules, tablets, dry powders for reconstitution, chewable tablets, dispersible tablets etc. Amoxicillin is available as tablets of different strengths such as 250 mg, 500 mg, 875 mg etc. The standard adult dose is 250 mg to 500 mg three times a day (tid). In addition, the 875 mg tablet is intended for
20 dosing twice daily (bid) instead of 500 mg tid. A high dose of 3 g, bid is recommended for treatment of recurrent purulent infection of respiratory tract. Use of 1 g Amoxicillin is recommended as one arm of combination therapy, for eradication of helicobacter pylori in peptic ulcer disease.

In the past, attempts have been made to develop modified release/controlled release
25 formulations of Amoxicillin. Such modified/controlled release tablets may provide better patient compliance since they need to be administered twice daily as compared to the 500 mg dose given tid.

European patent number EP1044680 discloses bilayered tablets comprising of an immediate release dose of a part of Amoxicillin and potassium clavulanate and a controlled release dose of a second part of Amoxicillin. The controlled release layer is a hydrophilic matrix. The above said composition suffers from the drawback that it requires excess quantities of excipients for preparing bilayered tablets. This combined with the high dose of Amoxicillin results in a product which is too bulky and difficult to administer.

US Patent no. 5,690,959 discloses a composition prepared using hydrophobic material manufactured by a process of thermal infusion. Amoxicillin, being temperature sensitive, may undergo degradation if subjected to high temperatures for longer periods of time.

US Patent no. 6,399,086 discloses a pharmaceutical composition of Amoxicillin wherein 50% of the drug is released within 3-4 hours. The said composition is based on hydrophilic erodible polymers.

US Patent no. 6,368,635 discloses a solid matrix composition which is solid at ambient temperature, which comprises a viscogenic agent, such as an acrylic acid polymer, capable of developing viscosity on contact with water, as dispersed at least in the neighborhood of the surface layer of a matrix particle containing a polyglycerol fatty acid ester or a lipid and an active ingredient. The matrix may be such that a matrix particle containing a polyglycerol fatty acid ester or a lipid and an active ingredient has been coated with a coating composition containing at least one viscogenic agent. Such composition can adhere to the digestive tract and remain there for a prolonged period of time, thereby increasing the bioavailability of the active ingredient. Such gastric mucosa-adherent particles have unpredictable residence time in the stomach and are highly influenced by the gastric contents. Bioavailability of active agents from such compositions are highly variable.

European patent no. EP0526862 discloses a pharmaceutical composition of Amoxicillin with prolonged residence due to high density of the composition. The said composition suffers from the drawback that non-uniform release of active ingredient results due to variable passage of tablet into intestine by virtue of density itself resulting in significant bioavailability loss.

Hilton and Deasy, [J. Pharm. Sci. 82(7):737-743 (1993)] describe a controlled-release tablet of Amoxicillin trihydrate based on the enteric polymer hydroxypropylmethyl cellulose acetate succinate. This polymer suppressed the release of the drug in the presence of gastric pH but could enhance its release in the small intestine. Therefore, such a formulation cannot give the desired burst effect outlined in the present invention. Single dose studies with a panel of fasting subjects showed that the tablets had a relative bioavailability of only 64.4%, probably because of the poorer absorption of Amoxicillin from the distal jejunum and ileum than from the duodenum and proximal jejunum. Other pharmacokinetic parameters confirmed a lack of therapeutic advantage of these factors over an equivalent dose of conventional capsule.

Hilton and Deasy [Int. J. Pharm. 86(1):79-88 (1992)] also describe a floating tablet of Amoxicillin trihydrate. A bilayer tablet was initially formed in which the controlled-release drug layer consisted of Amoxicillin and hydroxypropyl cellulose. This layer was bonded to a gas generating layer. However, when the two layers were joined together, the composite tablet failed to float and prematurely split along the joining of the two layers. Consequently, it was decided to abandon this approach in favor of a single-layer floating tablet. This tablet remained buoyant for 6 hours and had satisfactory in vitro sustained release. However, compared with conventional capsules in fasting humans at 500 mg equivalent dose of Amoxicillin, the relative bioavailability of the tablets were 80.5% and other pharmacokinetic parameters $T(0.1 \text{ mug/ml})$ and $T(0.5 \text{ mug/ml})$ corresponding to the length of time for which the serum levels remained greater than or equal to 0.1 mug/ml and 0.5 mug/ml, respectively, indicated lack of improved efficacy.

Uchida et al. [Chem. Pharm. Bull. 37(12):3416-3419 (1989)] describe a preparation of Amoxicillin, microencapsulated in ethyl cellulose. These micro-capsules exhibited a sustained-release effect when administered to dogs. However, such effect could be foreseen, since the gastric pH of the dogs which were tested, is considerably higher than human gastric pH (pH of about 6 in beagle dogs, compared to pH of about 2 in humans). The Amoxicillin is much less soluble at pH 6 than at pH 2. One would expect to obtain a very quick release of the drug from the same microcapsules if administered to humans. Hence, such combination would not provide a controlled release of Amoxicillin

Arancibia et al. [Int. J. Clin. Pharmacol. Ther. Toxicol. 25(2):97-100 (1987)] investigated the pharmacokinetics and bioavailability of Amoxicillin trihydrate. They refer to controlled-release tablets, the composition of which is not described. In any case, no drug was detectable after 8 hours from oral administration and therefore this
5 formulation had no advantage over conventional formulations.

Some of the compositions discussed in the art are prepared using hydrophilic swellable polymers. However, these compositions require the use of excessive quantities of release controlling agents. This combined with high dose of amoxicillin, results in a product, which is too bulky to administer orally. In addition, these products have significant food
10 effects resulting in variable bioavailability. Another approach available in the art involves the use of bioadhesive polymers. Such products are highly variable since bioadhesiveness is a property, which is significantly dependent of the gastric contents. Presence of food in the stomach reduces the bioadhesive property resulting in reduced bioavailability. A third approach discussed in the art uses enteric polymers. Since
15 Amoxicillin is predominantly absorbed from proximal part of small intestine, enteric release of the drug results in loss of bioavailability. Hence there still exists a need for developing controlled release compositions of amoxicillin, either alone or in combination with other antibiotic(s) devoid of limitations discussed above.

Summary of the invention

20 It is an objective of the present invention to provide rapidly disintegrating oral controlled release pharmaceutical composition comprising at least one active ingredient, and a polymer system comprising of at least two polymers wherein one is an acid insoluble polymer and the other is a bioadhesive polymer, which retard the release of the active ingredient in the stomach while providing rapid release of the said active ingredient in
25 the pH above 5.5, optionally with other pharmaceutically acceptable excipients.

It is an objective of the present invention to provide rapidly disintegrating oral controlled release pharmaceutical composition comprising at least one active ingredient preferably antibiotic, more preferably amoxicillin or its pharmaceutically acceptable salts, hydrates,
30 polymorphs, esters, and derivatives thereof.

It is a further objective of the present invention to provide controlled release composition comprising an antibiotic as an active ingredient in combination with at least one other antibiotic.

- 5 It is yet another objective of the present invention to provide process for the preparation of such composition which comprises of the following steps:
- i) mixing of active ingredient(s) and polymer(s),
 - ii) optionally adding one or more other pharmaceutically acceptable excipients, and
 - iii) formulation of the mixture into a suitable dosage form.

10

Detailed description of the invention

The present invention relates to rapidly disintegrating oral controlled release pharmaceutical composition comprising at least one active ingredient or its pharmaceutically acceptable salts, hydrates, polymorphs, esters, and derivatives thereof; and a polymer system, optionally with other pharmaceutically acceptable excipients. The polymer system comprises of at least two polymers, wherein one is an acid insoluble polymer and the other is a bioadhesive polymer. The polymer system retards the release of the active ingredient in the stomach while providing rapid release of the said active ingredient in the pH above 5.5.

- 20 In an embodiment, the present invention describes controlled release mucoadhesive, disintegrating type formulation of Amoxicillin, preferably in its trihydrate form. The said composition disintegrates into particles, which have increased residence time in the stomach thus maintaining concentrations above effective levels for extended periods of time. The controlled release formulation provides better patient compliance since they need to be administered twice daily as compared to 500 mg dose given tid.

25 The present invention also relates to controlled release compositions of preferably an antibiotic, more preferably amoxicillin trihydrate, either alone or in combination with other antibiotic(s) for maintaining concentrations above effective levels, for extended

periods of time. The release mechanism involves predominantly diffusion and the product is preferably in the form of a rapidly disintegrating tablet.

The controlled release compositions prepared according to the present invention provides for rapidly disintegrating tablet where the granules behave as controlled release particles.

- 5 These particles have a unique polymer combination to retard the release in the stomach while providing rapid dissolution in the alkaline contents of small intestine. In addition, the controlled release compositions have bioadhesive properties.

- In an embodiment of the present invention, the controlled release composition comprises an antibiotic as an active ingredient in combination with at least one other antibiotic. The
10 antibiotics are selected from but not limited to the group comprising amoxicillin, ampicillin, cloxacillin, clavulanic acid, cephalosporins, and the like.

- In an embodiment, the active ingredient of the present pharmaceutical composition is cephalexin, or its pharmaceutically acceptable salts, hydrates, polymorphs, esters, and
15 derivatives thereof.

- The polymer system of the present invention comprises of polymer system comprises of polymers selected from a group comprising polyvinyl pyrrolidone, polyvinyl acetate, methacrylic acid polymers, acrylic acid polymers, hydroxypropyl methylcellulose
20 phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, and alginates, cellulose derivative, polyethylene oxide, chitosans, and polycarbophil, or mixtures thereof. Preferably the polymer system comprises methacrylic acid polymer and polycarbophil.

- 25 The acid insoluble polymer of the present invention is selected form but not limited to a group comprising methacrylic acid polymers, acrylic acid polymers, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, alginates, and the like; or mixtures thereof and the other is a bioadhesive polymer is selected form but
30 not limited to a group comprising polycarbophil such as Noveon® AA1 (B. F. Goodrich

Specialty Polymers), and chitosans, or mixtures thereof. Polycarbophil is a polyacrylic acid that is cross-linked with divinyl glycol.

The methacrylic acid polymer is selected from a group comprising but not limited to
5 Eudragit® (Degussa) such as Eudragit® L-100, Ammonio Methacrylate Copolymer type A USP (Eudragit® RL), Ammonio Methacrylate Copolymer type B USP (Eudragit® RS), Eudragit® RSPO, Eudragit® RLPO, and Eudragit® RS30D.

In a preferred embodiment of the present invention, the rapidly disintegrating oral controlled release pharmaceutical composition comprises amoxicillin trihydrate; and a
10 polymer system comprising methacrylic acid polymer and polycarbophil, optionally with other pharmaceutically acceptable excipients.

In an embodiment of the present invention, the ratio of methacrylic acid polymer and polycarbophil is 20:1 to 1:20 by weight of the composition. Preferably the ratio of methacrylic acid polymer and polycarbophil is 10:1 to 1:10 by weight of the
15 composition.

In another preferred embodiment of the present invention, the composition additionally comprises a cellulose derivative, selected from but not limited to a group comprising alkyl cellulose such as ethyl cellulose, methyl cellulose, and the like; carboxyalkyl
20 cellulose such as carboxyethyl cellulose, carboxymethyl cellulose, carboxypropyl cellulose, and the like, and hydroxyalkyl cellulose such as hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, and the like, and hydroxypropyl alkyl cellulose such as hydroxypropyl methyl cellulose, and the like. Preferably, the cellulose derivative is alkyl cellulose such as ethylcellulose or propylcellulose.

25 The pharmaceutically acceptable excipients of the present invention are selected from the group comprising diluents disintegrants, binders, fillers, bulking agent, coating agents, plasticizers, organic solvents, colourants, stabilizers, preservatives, lubricants, glidants, chelating agents, and the like known to the art.

In an embodiment of the present invention is provided a process for preparation of
30 composition as herein described which comprises of the following steps:

- i) mixing of active ingredient(s) and polymer(s),
- ii) optionally adding one or more other pharmaceutically acceptable excipients, and
- iii) formulation of the mixture into a suitable dosage form.

In an embodiment, the composition of the present invention is in the form of tablets. The
 5 tablets can be prepared by either direct compression, dry compression (slugging), or by granulation.

The granulation technique is either aqueous or non-aqueous. Preferably, the tablets of the present invention are prepared by non-aqueous granulation technique. The non-aqueous solvent used is selected from a group comprising ethanol or isopropyl alcohol.

- 10 In yet another embodiment, the controlled release formulations prepared according to the present invention disintegrates into particles, which adhere to mucosa of the stomach. These particles provide for controlled release of Amoxicillin till the time they are retained in the stomach. Passage of these granules into the small intestine results in dissolution of release controlling polymers, thus liberating any residual drug entrapped in
 15 the particles. This unique combination of polymers provides for a controlled release formulation which does not result in significant loss of bioavailability. Such a formulation does not involve the use of swellable polymers, hydrophobic waxy materials. Such a product may be prepared using polymers like polyvinyl pyrrolidone, polyvinyl acetate, methacrylic acid polymers, acrylic acid polymers; and the like either
 20 alone or in combination thereof.

The controlled release composition of the present invention may be formulated as oral dosage forms such as tablets, capsules and the like.

- The examples given below serve to illustrate embodiments of the present invention.
 25 However they do not intend to limit the scope of present invention.

EXAMPLES

Example 1

A. Core granules

30	Ingredients	mg/tablet
	i) Amoxicillin trihydrate	- 860

(equivalent to 750 mg of Amoxicillin)

	ii)	Eudragit® L-100	-	180
	iii)	Polycarbophil	-	70
	iv)	Eudragit® L-100 (Binder)	-	20
5	v)	Isopropyl Alcohol	-	Lost in processing
	vi)	Dichloromethane	-	Lost in processing

Procedure:

1. Mix (i), (ii) and (iii).
- 10 2. Dissolve (iv) in 1:2 mixture of (v) and (vi).
3. Granulate the blend of step 1 with solution of step 2.
4. Pass the wet mass through sieve of mesh size 20 and dry.
5. Pass the dried granule through sieve of mesh size 30.

15 B. Coating of the granules in FBC (Fluid Bed Coater)

	Ingredients	% w/w
	i) Eudragit® L-100	- 12.5
	ii) Polycarbophil	- 0.625
	iii) Triethyl citrate	- 2.5
20	iv) Isopropyl alcohol	- q.s.
	v) Dichloromethane	- q.s.
	vi) Colour lake of Poncaou 4R	- 0.1

Procedure :

- 25 1. Mix (i) and (ii)
2. Pass (vi) through sieve of mesh no. 120.
3. Disperse the bulk of step 1 and 2 in 1 : 2 mixture of (iv) and (v).
4. Add (iii) to the bulk of step 3 and stir.
5. Coat the granules of part A in FBC with the solution B.

30

C. Compression

	Ingredient	mg/tablet
i)	Amoxicillin granules (coated in B)	- 1399.7
ii)	Microcrystalline cellulose	- 100.0

iii)	Croscarmellose sodium	-	50.0
iv)	Talc	-	10.0
v)	Magnesium stearate	-	10.0

Procedure:

- 5 1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
3. Compress the blended granules into tablets.

Example 2

10 A. Core granules

	Ingredients		mg/tablet
	i) Amoxicillin trihydrate	-	860
	(equivalent to 750 mg of Amoxicillin)		
	ii) Eudragit® L-100	-	150
15	iii) Polycarbophil	-	60
	iv) Eudragit® L-100 (Binder)	-	20
	v) Isopropyl alcohol	-	Lost in processing
	vi) Dichloromethane	-	Lost in processing

20 Procedure:

1. Mix (i), (ii) and (iii).
2. Dissolve (iv) in (v).
3. Granulate the mass of step 1 with solution of step 2.
4. Pass the wet mass through sieve of mesh size 20 and dry.
- 25 5. Pass the dried granule through sieve of mesh size 30.

B. Coating

	Ingredient		% w/w
	i) Eudragit® L-100	-	20.0
30	ii) Polycarbophil	-	1.0
	iii) Triethyl citrate	-	2.0
	iv) Isopropyl alcohol	-	q.s.
	v) Dichloromethane	-	q.s.
	vi) Colour lake of Poncaou 4R	-	0.1

Procedure :

1. Mix (i) and (ii)
2. Pass (vi) through sieve of mesh no. 120.
- 5 3. Disperse the bulk of step 1 and 2 in 1 : 2 mixture of (iv) and (v).
4. Add (iii) to the bulk of step 3 and stir for 45 minutes.
5. Coat the granules of part A in FBC with the solution B.

C. Compression

10	Ingredient		mg/tablet
	i) Amoxicillin granules (coated in B)	-	1310.0
	ii) Microcrystalline cellulose	-	150.0
	iii) Croscarmellose sodium	-	20.0
	iv) Talc	-	10.0
15	v) Magnesium stearate	-	10.0

Procedure:

1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
- 20 3. Compress the blended granules into tablets.

Example 3

A. Core granules

	Ingredients		mg/tablet
25	i) Amoxicillin trihydrate (equivalent to 750 mg of Amoxicillin)	-	860.00
	ii) Eudragit® L-100	-	180.00
	iii) Polycarbophil	-	70.00
	iv) PVP K-30	-	20.00
30	v) Purified Water	-	Lost in processing

Procedure:

6. Mix (i), (ii) and (iii) pass through mesh size 30.
7. Dissolve (iv) in water
- 35 8. Granulate the mass of step 1 with solution of step 2.

9. Pass the wet mass through sieve of mesh size 20 and dry.

10. Pass the dried granule through sieve of mesh size 30.

B. Coating of the granules in FBC (Fluid Bed Coater)

	Ingredients		% w/w
5	i)	Eudragit® NE 30 D - (Dry polymer weight of 30% w/w dispersion)	12.50
	ii)	Polycarbophil -	0.625
	iii)	Talc -	6.25
	iv)	Colour Lake of Ponceau 4R -	0.10
10	v)	Purified Water -	Lost in processing

Procedure:

6. Mix (ii), (iii) and (iv)
7. Pass mass of step 1 through sieve of mesh no. 100.
- 15 8. Disperse the bulk of step 2 in (v) and pass through a Colloid mill.
9. Add (i) to the bulk of step 3 and stir.
10. Coat the granules of part A in FBC with solution of step 4.

C. Compression

	Ingredients		mg/tablet
20	i)	Amoxicillin granules (coated in B) -	1350.09
	ii)	Microcrystalline cellulose -	100.00
	iii)	Croscarmellose sodium -	50.00
	iv)	Talc -	10.00
25	v)	Magnesium stearate -	10.00

Procedure:

4. Mix (ii), (iii), (iv) and (v)
5. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
- 30 6. Compress the blended granules into tablets.

Example 4**A. Core granules**

	Ingredients	mg/tablet
	i) Amoxicillin trihydrate	- 860.00
5	(equivalent to 750 mg of Amoxicillin)	
	ii) Eudragit® L-100	- 100.00
	iii) Polycarbophil	- 40.00
	iv) Eudragit® L-30-D55	- 150.00
	(Dry polymer weight of 30% w/w dispersion)	
10	v) Purified Water	- Lost in processing

Procedure:

1. Mix (i), (ii) and (iii) and pass through mesh size 30.
2. Disperse (iv) in water
- 15 3. Granulate the mass of step 1 with dispersion of step 2.
4. Pass the wet mass through sieve of mesh size 20 and dry.
5. Pass the dried granule through sieve of mesh size 30.

B. Coating of the granules in FBC (Fluid Bed Coater)

	Ingredients	% w/w
20	i) Eudragit® L-30-D55	- 12.50
	(Dry polymer weight of 30% w/w dispersion)	
	ii) Polycarbophil	- 0.625
	iii) Talc	- 6.25
25	iv) Triethyl Citrate	- 1.25
	v) Colour Lake of Ponceau 4R	- 0.10
	vi) Purified Water	- Lost in processing

Procedure :

- 30 1. Mix (ii), (iii) and (v).
2. Pass mass of step 1 through sieve of mesh no. 100.
3. Disperse the bulk of step 2 in (vi) and pass through a Colloid mill.
4. Add (i) and (iv) to the bulk of step 3 and stir.
5. Coat the granules of part A in FBC with solution of step 4.

C. Compression

	Ingredients		mg/tablet
	i) Amoxicillin granules (coated in B)	-	1388.34
5	ii) Microcrystalline cellulose	-	100.00
	iii) Croscarmellose sodium	-	50.00
	iv) Talc	-	10.00
	v) Magnesium stearate	-	10.00

10 Procedure:

1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
3. Compress the blended granules into tablets.

15 Example 5**A. Core granules**

	Ingredients		mg/tablet
	i) Amoxicillin trihydrate (equivalent to 750 mg of Amoxicillin)	-	860.00
20	ii) Eudragit® L-100	-	120.00
	iii) Polycarbophil	-	40.00
	iv) Eudragit® L-30-D55 (Dry polymer weight of 30% w/w dispersion)	-	80.00
	v) Purified Water	-	Lost in processing

25**Procedure:**

1. Mix (i), (ii) and (iii) pass through mesh size 30.
2. Disperse (iv) in water
3. Granulate the mass of step 1 with solution of step 2.
- 30 4. Pass the wet mass through sieve of mesh size 20 and dry.
5. Pass the dried granule through sieve of mesh size 30.

B. Coating of the granules in FBC (Fluid Bed Coater)

	Ingredients		% w/w
	i) Eudragit® L-30-D55	-	16.00
	(Dry polymer weight of 30% w/w dispersion)		
5	ii) Polycarbophil	-	0.09
	iii) Talc	-	8.00
	iv) Triethyl Citrate	-	3.20
	v) Colour Lake of Ponceau 4R	-	0.10
	vi) Purified Water	-	Lost in processing

10

Procedure :

1. Mix (ii), (iii) and (v).
2. Pass bulk of step 1 through sieve of mesh no. 100.
3. Disperse the bulk of step 2 in (vi) and pass through a Colloid mill.
- 15 4. Add (i) and (iv) to the bulk of step 3 and stir.
5. Coat the granules of part A in FBC with solution of step 4.

C. Compression

	Ingredients		mg/tablet
20	i) Amoxicillin granules (coated in B)	-	1401.29
	ii) Microcrystalline cellulose	-	100.00
	iii) Croscarmellose sodium	-	50.00
	iv) Talc	-	10.00
	v) Magnesium stearate	-	10.00

25

Procedure:

1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
3. Compress the blended granules into tablets.

30

Example 6**A. Core granules**

	Ingredients		mg/tablet
	i) Amoxicillin trihydrate	-	860.00

	(equivalent to 750 mg of Amoxicillin)		
	ii) Ethyl Cellulose M 20	-	100.00
	iii) Polycarbophil	-	40.00
	iv) Eudragit® L-30-D55	-	20.00
5	(Dry polymer weight of 30% w/w dispersion)		
	v) Purified Water	-	Lost in processing

Procedure:

1. Mix (i) and (iii) pass through mesh size 30.
- 10 2. Pass (ii) through sieve of mesh size 100 and blend with mass of step 1.
3. Disperse (iv) in Purified Water.
4. Granulate the mass of step 2 with solution of step 3.
5. Pass the wet mass through sieve of mesh size 20 and dry.
6. Pass the dried granule through sieve of mesh size 30.

15

B. Coating of the granules in FBC (Fluid Bed Coater)

	Ingredients		% w/w
	i) Eudragit® L-30-D55	-	12.50
	(Dry polymer weight of 30% w/w dispersion)		
20	ii) Talc	-	6.25
	iii) Triethyl Citrate	-	3.75
	iv) Colour Lake of Ponceau 4R	-	0.10
	v) Purified Water	-	Lost in processing

25 Procedure :

1. Mix (iii) and (v).
2. Pass mass of step 1 through sieve of mesh no. 100.
3. Disperse the bulk of step 2 in (v) and pass through a Colloid mill.
4. Add (i) and (iii) to the bulk of step 3 and stir.
- 30 5. Coat the granules of part A in FBC with solution of step 4.

C. Compression

	Ingredients		mg/tablet
i)	Amoxicillin granules (coated in B)	-	1251.34

ii)	Microcrystalline cellulose	-	100.00
iii)	Croscarmellose sodium	-	50.00
iv)	Talc	-	10.00
v)	Magnesium stearate	-	10.00

5

Procedure:

1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
3. Compress the blended granules into tablets.

10

Example 7**A. Core granules**

Ingredients	mg/tablet
-------------	-----------

i)	Amoxicillin trihydrate	-	860.00
	(equivalent to 750 mg of Amoxicillin)		
ii)	Ethyl Cellulose	-	20.00
iii)	Polycarbophil	-	40.00
iv)	Eudragit® L100	-	50.00
v)	Eudragit® L-30-D55	-	100.00
	(Dry polymer weight of 30% w/w dispersion)		
vi)	Purified Water	-	Lost in processing

Procedure:

1. Mix (i), (iii) and (iv) pass through mesh size 30.
2. Pass (ii) through sieve of mesh size 100 and blend with mass of step 1.
3. Disperse (v) in Purified Water.
4. Granulate the mass of step 2 with solution of step 3.
5. Pass the wet mass through sieve of mesh size 20 and dry.
6. Pass the dried granule through sieve of mesh size 30.

30

B. Coating of the granules in FBC (Fluid Bed Coater)

Ingredients	% w/w
i) Eudragit® L-30-D55	- 12.50
(Dry polymer weight of 30% w/w dispersion)	

	ii)	Polycarbophil	-	0.625
	iii)	Talc	-	6.25
	iv)	Triethyl Citrate	-	2.50
	v)	Colour Lake of Ponceau 4R	-	0.10
5	vi)	Purified Water	-	Lost in processing

Procedure :

1. Mix (ii), (iii) and (v).
2. Pass mass of step 1 through sieve of mesh no. 100. /
- 10 3. Disperse the bulk of step 2 in (vi) and pass through a Colloid mill.
4. Add (i) and (iv) to the bulk of step 3 and stir.
5. Coat the granules of part A in FBC with solution of step 4.

C. Compression

15		Ingredients		mg/tablet
	i)	Amoxicillin granules (coated in B)	-	1305.13
	ii)	Microcrystalline cellulose	-	100.00
	iii)	Croscarmellose sodium	-	50.00
	iv)	Talc	-	10.00
20	v)	Magnesium stearate	-	10.00

Procedure:

1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
- 25 3. Compress the blended granules into tablets.

Example 8

A. Core granules

		Ingredients		mg/tablet
30	i)	Amoxicillin trihydrate (equivalent to 750 mg of Amoxicillin)	-	860.00
	ii)	Eudragit® RSPO	-	100.00
	iii)	Polycarbophil	-	40.00
	iv)	Eudragit® L-30-D55	-	100.00

(Dry polymer weight of 30% w/w dispersion)

- v) Purified Water - Lost in processing

Procedure:

- 5 1. Mix (i), (ii) and (iii) pass through mesh size 30.
 2. Disperse (iv) in Purified Water.
 3. Granulate the mass of step 1 with solution of step 2.
 4. Pass the wet mass through sieve of mesh size 20 and dry.
 5. Pass the dried granule through sieve of mesh size 30.

10

B. Coating of the granules in FBC (Fluid Bed Coater)

	Ingredients	% w/w
i)	Eudragit® L-100	- 12.50
ii)	Polycarbophil	- 0.625
15 iii)	Triethyl Citrate	- 2.50
iv)	Isopropyl Alcohol	- Lost in processing
v)	Dichloromethane	- Lost in processing
vi)	Colour Lake of Ponceau 4R	- 0.10

20 Procedure :

1. Mix (i) and (ii) and pass through mesh no. 100.
 2. Pass (vi) through sieve of mesh no. 120.
 3. Disperse the bulk of step 1 and 2 in 1:2 mixture of (iv) and (v)
 4. Add (iii) to the bulk of step 3 and stir.
 5. Coat the granules of part A in FBC with solution of step 4.

25

C. Compression

	Ingredients	mg/tablet
i)	Amoxicillin granules (coated in B)	- 1272.97
30 ii)	Microcrystalline cellulose	- 100.00
iii)	Croscarmellose sodium	- 50.00
iv)	Talc	- 10.00
v)	Magnesium stearate	- 10.00

35

Procedure:

1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
3. Compress the blended granules into tablets.

5

Example 9**A. Core granules**

	Ingredients	mg/tablet
10	i) Amoxicillin trihydrate (equivalent to 750 mg of Amoxicillin)	- 860.00
	ii) Eudragit RLPO	- 100.00
	iii) Polycarbophil	- 40.00
	iv) Eudragit L-30-D55 (Dry polymer weight of 30% w/w dispersion)	- 100.00
15	v) Purified Water	- Lost in processing

Procedure:

1. Mix (i), (ii) and (iii) pass through mesh size 30.
2. Disperse (iv) in Purified Water
- 20 3. Granulate the mass of step 1 with solution of step 2.
4. Pass the wet mass through sieve of mesh size 20 and dry.
5. Pass the dried granule through sieve of mesh size 30.

B. Coating of the granules in FBC (Fluid Bed Coater)

	Ingredients	% w/w
25	i) Eudragit L-100	- 12.50
	ii) Polycarbophil	- 0.625
	iii) Triethyl Citrate	- 2.50
	iv) Isopropyl Alcohol	- Lost in processing
	v) Dichloromethane	- Lost in processing
30	vi) Colour Lake of Ponceau 4R	- 0.10

Procedure :

1. Mix (i) and (ii) and pass through mesh no. 100.
2. Pass (vi) through sieve of mesh no. 120.

3. Disperse the bulk of step 1 and 2 in 1:2 mixture of (iv) and (v)
4. Add (iii) to the bulk of step 3 and stir.
5. Coat the granules of part A in FBC with solution of step 4.

5 C. Compression

	Ingredient		mg/tablet
	i) Amoxicillin granules (coated in B)	-	1272.97
	ii) Microcrystalline cellulose	-	100.00
	iii) Croscarmellose sodium	-	50.00
10	iv) Talc	-	10.00
	v) Magnesium stearate	-	10.00

Procedure:

1. Mix (ii), (iii), (iv) and (v)
- 15 2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
3. Compress the blended granules into tablets.

Example 10

A. Core granules

	Ingredients		mg/tablet
20	i) Amoxicillin trihydrate (equivalent to 750 mg of Amoxicillin)	-	860.00
	ii) Eudragit RLPO	-	100.00
	iii) Polycarbophil	-	40.00
25	iv) Triethyl Citrate	-	20.00
	v) Eudragit L-30-D55 (Dry polymer weight of 30% w/w dispersion)	-	100.00
	vi) Purified Water	-	Lost in processing

30 Procedure:

1. Mix (i), (ii) and (iii) pass through mesh size 30.
2. Disperse (iv) and (v) in water
3. Granulate the mass of step 1 with solution of step 2.
4. Pass the wet mass through sieve of mesh size 20 and dry.

5. Pass the dried granule through sieve of mesh size 30.

B. Coating of the granules in FBC (Fluid Bed Coater)

	Ingredients		% w/w
5	i)	Eudragit L-100	- 12.50
	ii)	Polycarbophil	- 0.625
	iii)	Triethyl Citrate	- 2.50
	iv)	Isopropyl Alcohol	- Lost in processing
	v)	Dichloromethane	- Lost in processing
10	vi)	Colour Lake of Ponceau 4R	- 0.10

Procedure :

1. Mix (i) and (ii) pass through mesh no. 100.
2. Pass (vi) through sieve of mesh no. 120.
- 15 3. Disperse the bulk of step 1 and 2 in 1:2 mixture of (iv) and (v)
4. Add (iii) to the bulk of step 3 and stir.
5. Coat the granules of part A in FBC with solution of step 4.

C. Compression

	Ingredients		mg/tablet
20	i)	Amoxicillin granules (coated in B)	- 1296.12
	ii)	Microcrystalline cellulose	- 100.00
	iii)	Croscarmellose sodium	- 50.00
	iv)	Talc	- 10.00
25	v)	Magnesium stearate	- 10.00

Procedure:

1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
- 30 3. Compress the blended granules into tablets.

Example 11**A. Core granules**

	Ingredients	mg/tablet
5	i) Amoxicillin trihydrate (equivalent to 750 mg of Amoxicillin)	- 860.00
	ii) Eudragit RLPO	- 100.00
	iii) Polycarbophil	- 40.00
	iv) Triethyl Citrate	- 20.00
10	iv) Eudragit L-30-D55 (Dry polymer weight of 30% w/w dispersion)	- 100.00
	v) Purified Water	- Lost in processing

Procedure:

- 15 1. Mix (i), (ii) and (iii) pass through mesh size 30.
2. Disperse (iv) and (v) in Purified Water.
3. Granulate the mass of step 1 with solution of step 2.
4. Pass the wet mass through sieve of mesh size 20 and dry.
5. Pass the dried granule through sieve of mesh size 30.

20

B. Coating of the granules in FBC (Fluid Bed Coater)

	Ingredients	% w/w
	i) Ethyl cellulose (Surelease®) (Dry polymer weight of 25% w/w dispersion)	- 12.50
25	ii) Polycarbophil	- 0.18
	iii) Talc	- 6.25
	iv) Triethyl Citrate	- 2.50
	v) Colour Lake of Ponceau 4R	- 0.10
	vi) Water	- Lost in processing

30

Procedure :

1. Mix (ii), (iii) and (v).
2. Pass mass of step 1 through sieve of mesh no. 100.
3. Disperse the bulk of step 2 in (vi) and pass through a Colloid mill.

4. Add (i) and (iv) to the bulk of step 3 and stir.
5. Coat the granules of part A in FBC with solution of step 4.

C. Compression

5	Ingredient	mg/tablet
i)	Amoxicillin granules (coated in B)	- 1361.14
ii)	Microcrystalline cellulose	- 100.00
iii)	Croscarmellose sodium	- 50.00
iv)	Talc	- 10.00
10 v)	Magnesium stearate	- 10.00

Procedure:

1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
- 15 3. Compress the blended granules into tablets.

Example 12**A. Core granules**

	Ingredients	mg/tablet
20 i)	Amoxicillin trihydrate (equivalent to 750 mg of Amoxicillin)	- 860.00
ii)	Eudragit L-100	- 100.00
iii)	Polycarbophil	- 40.00
iv)	Eudragit L100	- 20.00
25 v)	Ethanol	- Lost in processing
vi)	Purified Water	- Lost in processing

Procedure:

1. Mix (i), (ii) and (iii) pass through mesh size 30.
- 30 2. Dissolve (iv) in a mixture of (v) and (vi) (6:4 ratio)
3. Granulate the mass of step 1 with solution of step 2.
4. Pass the wet mass through sieve of mesh size 20 and dry.
5. Pass the dried granule through sieve of mesh size 30.

B. Coating of the granules in FBC (Fluid Bed Coater)

	Ingredients		% w/w
	i) Eudragit L-100	-	12.50
	ii) Polycarbophil	-	0.625
5	iii) Triethyl Citrate	-	2.50
	iv) Isopropyl Alcohol	-	Lost in processing
	v) Dichloromethane	-	Lost in processing
	vi) Colour Lake of Ponceau 4R	-	0.10

10 Procedure :

1. Mix (i) and (ii) and pass through mesh no. 100.
2. Pass (vi) through sieve of mesh no. 120.
3. Disperse the bulk of step 1 and 2 in 1:2 mixture of (iv) and (v)
4. Add (iii) to the bulk of step 3 and stir.

- 15 5. Coat the granules of part A in FBC with solution of step 4.

C. Compression

	Ingredient		mg/tablet
	i) Amoxicillin granules (coated in B)	-	1180.39
20	ii) Microcrystalline cellulose	-	100.00
	iii) Croscarmellose sodium	-	50.00
	iv) Talc	-	10.00
	v) Magnesium stearate	-	10.00

25 Procedure:

1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
3. Compress the blended granules into tablets.

30 Example 13**A. Core granules**

	Ingredients		mg/tablet
	i) Amoxicillin trihydrate	-	860.00
	(equivalent to 750 mg of Amoxicillin)		

	ii)	Eudragit L-100	-	100.00
	iii)	Polycarbophil	-	40.00
	iv)	Eudragit L100	-	20.00
	v)	Ethanol	-	Lost in processing
5	vi)	Purified Water	-	Lost in processing

Procedure:

1. Mix (i), (ii) and (iii) pass through mesh size 30.
2. Dissolve (iv) in a mixture of (v) and (vi) (6:4 ratio)
- 10 3. Granulate the mass of step 1 with solution of step 2.
4. Pass the wet mass through sieve of mesh size 20 and dry.
5. Pass the dried granule through sieve of mesh size 30.

B. Coating of the granules in FBC (Fluid Bed Coater)

15		Ingredients		% w/w
	i)	Eudragit L-100	-	12.50
	ii)	Clavulanate Potassium	-	12.25
	iii)	Polycarbophil	-	0.625
	iv)	Triethyl Citrate	-	2.50
20	v)	Isopropyl Alcohol	-	Lost in processing
	vi)	Dichloromethane	-	Lost in processing
	vii)	Colour Lake of Ponceau 4R	-	0.10

Procedure :

- 25 1. Mix (i), (ii) and (iii).
2. Pass (vii) through sieve of mesh no. 120.
3. Disperse the bulk of step 1 and 2 in 1:2 mixture of (v) and (vi)
4. Add (iv) to the bulk of step 3 and stir.
5. Coat the granules of part A in FBC with solution of step 4.

30

C. Compression

		Ingredient		mg/tablet
	i)	Amoxicillin granules (coated in B)	-	1305.34
	ii)	Microcrystalline cellulose	-	100.00

iii)	Croscarmellose sodium	-	50.00
iv)	Talc	-	10.00
v)	Magnesium stearate	-	10.00

5 Procedure:

1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)
3. Compress the blended granules into tablets.

10 Example 14

A. Core granules

	Ingredients		mg/tablet
	i) Amoxicillin trihydrate	-	860.00
	(equivalent to 750 mg of Amoxicillin)		
15	ii) Eudragit L-100	-	100.00
	iii) Polycarbophil	-	40.00
	iv) Eudragit L100	-	20.00
	v) Ethanol	-	Lost in processing
	vi) Purified Water	-	Lost in processing

20

Procedure:

1. Mix (i), (ii) and (iii) pass through mesh size 30.
2. Dissolve (iv) in a mixture of (v) and (vi) (6:4 ratio)
3. Granulate the mass of step 1 with solution of step 2.
- 25 4. Pass the wet mass through sieve of mesh size 20 and dry.
5. Pass the dried granule through sieve of mesh size 30.

B. Coating of the granules in FBC (Fluid Bed Coater)

	Ingredients		% w/w
30	i) Eudragit L-100	-	12.50
	ii) Polycarbophil	-	0.625
	iii) Triethyl Citrate	-	2.50
	iv) Isopropyl Alcohol	-	Lost in processing
	v) Dichloromethane	-	Lost in processing

vi) Colour Lake of Ponceau 4R - 0.10

Procedure :

1. Mix (i) and (ii) and pass through mesh no. 100.
- 5 2. Pass (vi) through sieve of mesh no. 120.
3. Disperse the bulk of step 1 and 2 in 1:2 mixture of (iv) and (v)
4. Add (iii) to the bulk of step 3 and stir.
5. Coat the granules of part A in FBC with solution of step 4.

10

C. Preparation of Amoxicillin SR granules

	Ingredient		mg/tablet
	i) Amoxicillin granules (coated in B)	-	1180.39
	ii) Microcrystalline cellulose	-	100.00
15	iii) Croscarmellose sodium	-	50.00
	iv) Talc	-	10.00
	v) Magnesium stearate	-	10.00

Procedure:

- 20 1. Mix (ii), (iii), (iv) and (v)
2. Pass the mixture of step 1 through mesh no. 40 and blend with (i)

D. Preparation of Claculanate Potassium granules

	Ingredient		mg/tablet
25	i) Clavulanate Potassium/ Microcrystalline Cellulose 1:1 mixture (equivalent to 125 mg Clavulanic acid)	-	250.00
	ii) Croscarmellose sodium	-	50.00
	iii) Talc	-	10.00
30	iv) Magnesium stearate	-	10.00

Procedure:

1. Mix (i), (ii), (iii) and (iv)
2. Slug and de-slug the blend of step 1 and pass through sieve of mesh size 30.

35

E. Compression into Inlay tablets

- Compress the granules of Amoxicillin SR granules and Clavulanate potassium granules into inlay tablets where the Clavulanate potassium granules are inlayed into the tablet of
- 5 amoxicillin granules.

CLAIMS

1. A rapidly disintegrating oral controlled release pharmaceutical composition comprising at least one active ingredient, and a polymer system comprising of at least two polymers wherein one is an acid insoluble polymer and the other is a bioadhesive polymer, which retard the release of the active ingredient in the stomach while providing rapid release of the said active ingredient in the pH above 5.5, optionally with other pharmaceutically acceptable excipients.
5
2. A composition according to claim 1, wherein said active ingredient is selected from a group comprising antibiotics, such as cephalosporins and penicillins, and their pharmaceutically acceptable salts, hydrates, polymorphs, esters, and derivatives thereof.
10
3. A composition according to claim 1, wherein said active ingredient is amoxicillin trihydrate.
4. A composition according to claim 1, wherein said active ingredient is cephalexin, or its pharmaceutically acceptable salts, hydrates, polymorphs, esters, and derivatives thereof.
15
5. A composition according to claim 1, which comprises at least two active ingredients selected from the group comprising amoxicillin, ampicillin, cloxacillin, clavulanic acid, cephalosporins, or pharmaceutically acceptable salts or derivatives thereof.
20
6. A composition according to claim 1, wherein the polymer system comprises of polymers selected from a group comprising polyvinyl pyrrolidone, polyvinyl acetate, methacrylic acid polymers, acrylic acid polymers, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, and alginates, cellulose derivative, polyethylene oxide, chitosans, and polycarbophil, or mixtures thereof.
25
7. A composition according to claim 1, wherein the acid insoluble polymer is selected from a group comprising methacrylic acid polymers, acrylic acid

polymers, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, and alginates, or mixtures thereof.

8. A composition according to claim 1, wherein the bioadhesive polymer is selected
5 from a group comprising polycarbophil such as Noveon® AA1, and chitosans.
9. A composition according to claim 6, wherein the polymer system comprises methacrylic acid polymer and polycarbophil.
10. A composition according to claim 9, wherein the methacrylic acid polymer is
10 selected from a group comprising Eudragit® L-100, Eudragit® RS, and Eudragit® LS.
11. A composition according to claims 1-10, which additionally comprises a cellulose derivative.
12. A composition according to claim 11, wherein the cellulose derivative is selected
15 from a group comprising alkyl cellulose such as ethylcellulose and carboxyalkyl cellulose.
13. A composition according to claim 12, wherein the cellulose derivative is alkyl cellulose such as ethylcellulose.
14. A composition according to claims 9 to 13, wherein the ratio of methacrylic acid polymer and polycarbophil is 10:1 to 1:10 by weight of the composition.
- 20 15. A composition according to claim 1, wherein the pharmaceutically acceptable excipients are selected from the group comprising diluents disintegrants, binders, fillers, bulking agent, coating agents, plasticizers, organic solvents, colourants, stabilizers, preservatives, lubricants, glidants, chelating agents, and the like.
16. A composition according to claims 1-15, which is formulated as tablets or
25 capsules.
17. A process for preparation of a composition according to claim 1 which comprises of the following steps:

- i) mixing of active ingredient(s) and polymer(s),
 - ii) optionally adding one or more other pharmaceutically acceptable excipients, and
 - iii) formulation of the mixture into a suitable dosage form.
- 5 18. A process according to claim 17, wherein said active ingredient is selected from a group comprising antibiotics, such as cephalosporins and penicillins, and their pharmaceutically acceptable salts, hydrates, polymorphs, esters, and derivatives thereof.
- 10 19. A process according to claim 17, wherein said active ingredient is amoxicillin trihydrate.
20. A process according to claim 17, wherein said active ingredient is cephalexin, or its pharmaceutically acceptable salts, hydrates, polymorphs, esters, and derivatives thereof.
- 15 21. A process according to claim 17, which comprises at least two active ingredients selected from the group comprising amoxicillin, ampicillin, cloxacillin, clavulonic acid, and cephalosporins, or pharmaceutically acceptable salts or derivatives thereof.
- 20 22. A process according to claim 17, wherein the polymer system comprises of polymers selected from a group comprising polyvinyl pyrrolidone, polyvinyl acetate, methacrylic acid polymers, acrylic acid polymers, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, and alginates, cellulose derivative, polyethylene oxide, chitosans, and polycarbophil, or mixtures thereof.
- 25 23. A process according to claim 17, wherein the acid insoluble polymer is selected from a group comprising methacrylic acid polymers, acrylic acid polymers, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, and alginates, or mixtures thereof.

24. A process according to claim 17, wherein bioadhesive polymer is selected from a group comprising polycarbophil such as Noveon® AA1, and chitosans.
25. A process according to claim 22, wherein the polymer system comprises methacrylic acid polymer and polycarbophil.
- 5 26. A process according to claim 25, wherein the methacrylic acid polymer is selected from a group comprising Eudragit® L-100, Eudragit® RS, and Eudragit® LS.
27. A process according to claims 17-26, wherein the composition additionally comprises a cellulose derivative.
- 10 28. A process according to claim 27, wherein the cellulose derivative is selected from a group comprising alkyl cellulose such as ethylcellulose and carboxyalkyl cellulose.
29. A process according to claim 28, wherein the cellulose derivative is alkyl cellulose such as ethylcellulose.
- 15 30. A process according to claims 25-29, wherein the ratio of methacrylic acid polymer and polycarbophil is 10:1 to 1:10 by weight of the composition.
31. The pharmaceutical composition substantially as herein described and illustrated by the examples.
- 20 32. The process for the preparation of a pharmaceutical composition substantially as herein described and illustrated by the examples.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IN2005/000005

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/43 A61K9/26

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TIROSH B ET AL: "The effect of Eudragit RL-100 on the mechanical and mucoadhesion properties of polycarbophil dosage forms" JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 45, no. 1, 3 March 1997 (1997-03-03), pages 57-64, XP004524233 ISSN: 0168-3659	1,2,6-9, 14-18, 22-26,30
Y	abstract paragraph '02.6! paragraph '2.10! ----- -/--	3-5, 19-21

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

18 May 2005

Date of mailing of the international search report

02/06/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Sindel, U

INTERNATIONAL SEARCH REPORT

Inter' nal Application No
PCT/IN2005/000005

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LORENZO-LAMOSA M L ET AL: "Design of microencapsulated chitosan microspheres for colonic drug delivery." JOURNAL OF CONTROLLED RELEASE : OFFICIAL JOURNAL OF THE CONTROLLED RELEASE SOCIETY. 2 MAR 1998, vol. 52, no. 1-2, 2 March 1998 (1998-03-02), pages 109-118, XP002328395 ISSN: 0168-3659 paragraph '03.2! abstract -----	1,6-8, 10,16
X	WO 01/76562 A (NOVASSO OY; SAEKKINEN, MIA; MARVOLA, MARTTI) 18 October 2001 (2001-10-18) example 2 claims 1,8 -----	1,6-8, 17, 22-24,30
Y	REMUNAN-LOPEZ C ET AL: "Development of new chitosan-cellulose multicore microparticles for controlled drug delivery" EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 45, no. 1, January 1998 (1998-01), pages 49-56, XP004256936 ISSN: 0939-6411 abstract page 49, column 2, paragraph 1 figure 6 -----	11-13, 27-29
Y	WO 94/00112 A (AKTIEBOLAGET ASTRA) 6 January 1994 (1994-01-06) claim 1 example 4 page 5, line 17 - line 21 -----	11-13, 27-29
Y	US 6 399 086 B1 (KATZHENDLER IFAT ET AL) 4 June 2002 (2002-06-04) example 2 claims 1,10,15 -----	3-5, 19-21
A	LEHR C-M ET AL: "INTESTINAL TRANSIT OF BIOADHESIVE MICROSPHERES IN AN IN-SITU LOOP IN THE RAT A COMPARATIVE STUDY WITH COPOLYMERS AND BLENDS BASED ON POLY-ACRYLIC ACID" JOURNAL OF CONTROLLED RELEASE, vol. 13, no. 1, 1990, pages 51-62, XP002328396 ISSN: 0168-3659 abstract table 1 ----- -/--	1-32

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IN2005/000005

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>TORRE P M ET AL: "Release of amoxicillin from polyionic complexes of chitosan and poly(acrylic acid). study of polymer/polymer and polymer/drug interactions within the network structure" BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 24, no. 8, April 2003 (2003-04), pages 1499-1506, XP004401483 ISSN: 0142-9612 abstract page 1500, column 1, last paragraph page 1505, column 1, paragraph 2</p> <p>-----</p>	1-32
A	<p>US 5 910 322 A (RIVETT ET AL) 8 June 1999 (1999-06-08) example 2</p> <p>-----</p>	1-32

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/IN2005/000005

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0176562	A	18-10-2001	FI 20000780 A AU 5229601 A WO 0176562 A1	04-10-2001 23-10-2001 18-10-2001
WO 9400112	A	06-01-1994	AU 4517893 A WO 9400112 A1 SI 9300330 A	24-01-1994 06-01-1994 31-12-1993
US 6399086	B1	04-06-2002	IL 119627 A AU 4882597 A EP 0941064 A1 WO 9822091 A1	10-03-2002 10-06-1998 15-09-1999 28-05-1998
US 5910322	A	08-06-1999	AT 200981 T DE 69520882 D1 DE 69520882 T2 EP 0776206 A1 JP 10504818 T WO 9604908 A1 US 6299903 B1	15-05-2001 13-06-2001 10-01-2002 04-06-1997 12-05-1998 22-02-1996 09-10-2001